Brief: Apexigen Says Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, In Combination With Doxorubicin Marked Increases In Overall Survival Observed Across Soft Tissue Sarcoma Patients
03/06/2023 13:17
June 3 (Reuters) - Apexigen Inc APGN.O :
* APEXIGEN ANNOUNCES PHASE 2 DATA EVALUATING SOTIGALIMAB,
ITS CD40
AGONIST ANTIBODY, IN COMBINATION WITH DOXORUBICIN IN PATIENTS
WITH ADVANCED SOFT TISSUE SARCOMA PRESENTED AT THE AMERICAN
SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2023 ANNUAL MEETING
* APEXIGEN INC SAYS MARKED INCREASES IN OVERALL SURVIVAL
OBSERVED
ACROSS SOFT TISSUE SARCOMA PATIENTS
* APEXIGEN INC SAYS DEMONSTRATED IMPROVEMENT OF MEDIAN
PROGRESSION
FREE SURVIVAL IN PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA
(DDLPS)
* APEXIGEN INC SAYS DDLPS EXPANSION COHORT ENROLLING TO
INFORM A
POTENTIAL PHASE 3 REGISTRATION TRIAL
Source text for Eikon: ID:nGNX27D8fS
Further company coverage: APGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apexigen
See all newsBrief: Apexigen Inc - On August 15, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Apexigen Says Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, In Combination With Doxorubicin Marked Increases In Overall Survival Observed Across Soft Tissue Sarcoma Patients
Apexigen rises on buyout deal with Pyxis Oncology
Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
Brief: Apexigen Inc Says On April 11, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq